4506.T
The company operates in the pharmaceuticals industry, generating revenue primarily through the development, manufacturing, and sale of prescription drugs and related healthcare products.
Business. The company operates in the pharmaceuticals industry, generating revenue primarily through the development, manufacturing, and sale of prescription drugs and related healthcare products.
Analyst recommendations
6 analysts · consensus HoldAt a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
The company operates in the pharmaceuticals industry, generating revenue primarily through the development, manufacturing, and sale of prescription drugs and related healthcare products.
The company maintains a capital structure with a debt-to-equity ratio of 1.85, indicating a relatively high level of leverage. Its liquidity position is characterized by a current ratio of 1.05, suggesting limited short-term liquidity cushion. Free cash flow of 36.16 billion JPY supports operational flexibility, but the company's long-term debt of 314.25 billion JPY raises concerns about long-term solvency.
Profitability metrics show a return on equity of 13.95%, which is strong, but the return on assets of 3.18% is relatively low, indicating inefficient use of assets to generate returns. Gross profit of 245.50 billion JPY supports a solid margin, but operating income of 28.80 billion JPY and net income of 23.63 billion JPY suggest pressure from operating expenses and taxes.
The company's revenue is concentrated in a single business segment, with no disclosed geographic diversification. This lack of diversification increases exposure to regional economic and regulatory risks.
Outlook for the current fiscal year shows a modest growth trajectory, with revenue expected to remain stable. Analysts project a mean price target of 2,180.00 JPY, with a median of 2,200.00 JPY, indicating a generally positive but cautious sentiment.
Risk factors include a medium liquidity risk due to the current ratio and a negative net cash position after subtracting total debt. Dilution risk is assessed as low, with no significant dilution potential in the near term.
Recent events include analyst estimates and price targets, with a mean recommendation of 2.67, indicating a mixed outlook. No recent filings or transcripts have been disclosed that would significantly alter the company's strategic direction.
- The company has a strong return on equity but a weak return on assets, indicating asset inefficiency.
- High leverage and a negative net cash position raise concerns about long-term solvency.
- Analysts project a cautious outlook with a mean price target of 2,180.00 JPY.
- The company's lack of geographic and segment diversification increases exposure to regional and business-specific risks.
- Liquidity is limited, with a current ratio of 1.05 and no significant dilution risk in the near term.
Bull / Bear case
analysis pipelineIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
| Metric | Our forecast | Guidance | Consensus |
|---|---|---|---|
| EPS | —no estimate | —no estimate | 235,86 |
| Revenue | —no estimate | —no estimate | 439,5B JPY |
| Operating income | —no estimate | —no estimate | —no estimate |
Options
Short squeeze
Earnings-call key lines
Consensus distribution
sell-side coverageEstimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- Net cash is negative after subtracting total debt.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Capex To Revenuecapital_expenditure / revenue
- Return On Equitynet_income / total_equity
- Debt To Equity(short_term_debt + long_term_debt) / total_equity
- Cash Conversion Ratiooperating_cash_flow / net_income
- 4506.T Market data — financials · 2026-05-26
- Sumitomo Pharma Co Ltd Market data — analyst estimates · 2026-05-26